Billy's vision is to change the way we currently diagnose and monitor serious disease. He is the co-founder of Owlstone, which aims to become the global leader in the non-invasive detection of cancer, infectious disease and inflammatory disease.
It is best to detect disease as early as possible: treatments are more effective, less involved and more lives can be saved. There is no better example of this than with cancer. If detected early, the chances of cancer survival can be as good at 95%. But this drops massively to about 5% at later stages. Unfortunately there are still far too many people detected at later stage.
To address this, Owlstone Medical has developed a breathalyzer for disease. Every time you breathe out there are hundreds of chemicals on your breath. Some are telltale markers of disease, which Owlstone microchip chemical sensor technology is able to detect. Through early detection Owlstone have set a goal to have saved 100,000 lives and $1.5 billion in health care costs by 2020.
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners and is heavily involved in the creation and realisation of new technologies and IP. He is also active in business development, demonstrating how the Owlstone technology can be a paradigm shift in detection applications and deployment scenarios.
Prior to his time at Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.